We and others demonstrated that progression of cancers such as melanoma [3,4], breast [5], and bladder cancer [6,7] is catalyzed by the abundant expression of E2F1 and E2F1-mediated activation of downstream pro-metastatic gene regulatory networks (GRNs). The gene discussed is E2F1; the disease is urinary bladder carcinoma.